AstraZeneca Selects IT Contractor for Three Neuroscience Trials
The IT services, which include an electronic trial master file tool and cloud technology to share documents securely, will help AstraZeneca’s Neuroscience Innovative Medicines program.
The virtual program uses about 40 neuroscientists in Boston, Massachusetts, and Cambridge, UK, to manage a portfolio of drug discovery and development projects with other investigators, CROs (contract research organizations), academic researchers and regulatory authorities.
ePharmaSolutions CEO Lance Converse told Outsourcing-Pharma.com that the company is providing, among other things, “clinical trial portal and electronic trial master file solutions to support [AstraZeneca’s] interest in streamlining and accelerating the clinical development process.”
He also noted that his company has an internal team of physician and PhD psychiatrists who provide endpoint “rater training and rater reliability services” for the global studies.
Steven Leventer, PhD, VP of AstraZeneca praised the ePharmaSolutions products, noting that the company’s capabilities “are aimed at enabling the AZ NS iMed to ramp up our clinical trial sites more quickly and efficiently."
ePharmaSolutions also has a history of working with such trials. Converse added that his company currently has “330,000 users in 130 countries who currently use our integrated solution on more than 2500 active clinical trials.”
He also said more biopharmaceutical companies and CROs are signing on to use the IT services as they “realize the benefits of a fully electronic end-to-end solution.”
